
A new melanoma vaccine has shown its mettle in battling the deadly skin cancer in a new trial. People with advanced melanomas who received the vaccine plus Merck’s cancer drug Keytruda were 49% less likely to die or have their cancer return after three years than those who were given only Keytruda, vaccine maker Moderna… read on > read on >